Roundup Settlement Showdown: Legal Battle Over $7.25 Billion Class-Action Deal
A legal battle is brewing over a $7.25 billion class-action settlement involving Roundup, a popular weed killer. Lawyers representing individuals who believe they have been harmed by Roundup are challenging the settlement, calling it a "sweetheart deal" for the company. They argue that the settlement does not adequately compensate those affected by Roundup and provides too much protection for the company. The lawyers are seeking to move the case from state court to federal court, potentially delaying the settlement process.
The legal maneuver by the lawyers is expected to postpone the June 4 deadline for affected individuals to decide whether to participate in the settlement. This delay could also impact the timing of a Supreme Court decision on whether Roundup lawsuits claiming the product needed a cancer warning label should proceed. The uncertainty surrounding the Supreme Court's decision complicates the decision-making process for Roundup users considering the settlement offer.
Bayer, the pharmaceutical company that acquired Roundup maker Monsanto in 2018, is hoping that the Supreme Court ruling and the settlement will limit its future liability. The company is also advocating for legislation to protect itself from further lawsuits. The tight timeline of the settlement deal has raised concerns among critics, who believe it was rushed to pressure affected individuals into accepting the terms.
The Environmental Protection Agency has not classified Roundup as a cancer risk and does not require a warning label for the product. The Supreme Court is currently deliberating on whether Roundup users who have developed cancer can sue under state laws governing dangerous products. The outcome of this case could have significant implications for future lawsuits against Roundup.